PubRank

Arthur A Vandenbark

Author PubWeight™ 105.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 2006 3.91
2 Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol 2006 3.28
3 T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab 2007 2.75
4 Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005 2.39
5 GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol 2007 1.78
6 Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004 1.77
7 Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci 2011 1.63
8 Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 2007 1.59
9 Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003 1.53
10 The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol 2003 1.49
11 Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 2009 1.46
12 Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006 1.46
13 Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol 2003 1.37
14 Recombinant T cell receptor ligand treats experimental stroke. Stroke 2009 1.33
15 CD4+FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metab Brain Dis 2010 1.33
16 A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci 2007 1.31
17 Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol 2004 1.30
18 Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008 1.29
19 Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006 1.26
20 Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 2003 1.26
21 Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol 2010 1.25
22 Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005 1.24
23 Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J Neurosci 2009 1.18
24 Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 2009 1.16
25 Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury. J Immunol 2005 1.11
26 IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis 2013 1.11
27 Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis 2011 1.09
28 Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurosci Res 2002 1.09
29 Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 2002 1.07
30 Characterization of human platelet binding of recombinant T cell receptor ligand. J Neuroinflammation 2010 1.07
31 Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. J Neuroimmunol 2010 1.05
32 RTL therapy for multiple sclerosis: a Phase I clinical study. J Neuroimmunol 2010 1.04
33 Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J Neurosci Res 2010 1.04
34 Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis 2013 1.04
35 Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol 2013 1.04
36 Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice. Transl Stroke Res 2013 1.03
37 Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke 2011 1.03
38 Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol 2009 1.03
39 T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am J Pathol 2004 1.03
40 Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin Immunol 2007 1.02
41 Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice. Am J Pathol 2004 1.01
42 Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J Immunol 2006 1.01
43 T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. J Neurosci Res 2004 1.00
44 MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J Immunol 2008 1.00
45 Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol 2011 1.00
46 PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation 2013 0.99
47 Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004 0.99
48 Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metab Brain Dis 2011 0.99
49 Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci 2008 0.98
50 Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice. Metab Brain Dis 2012 0.98
51 IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol 2008 0.98
52 Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 2007 0.97
53 Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen. Clin Cancer Res 2005 0.96
54 Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005 0.95
55 Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology 2010 0.95
56 Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res 2004 0.95
57 A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. Metab Brain Dis 2014 0.95
58 Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis 2011 0.95
59 Estrogen inhibits systemic T cell expression of TNF-alpha and recruitment of TNF-alpha(+) T cells and macrophages into the CNS of mice developing experimental encephalomyelitis. Clin Immunol 2002 0.94
60 Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 2004 0.94
61 Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia. Transl Stroke Res 2011 0.94
62 PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. J Clin Cell Immunol 2013 0.94
63 Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Dis 2012 0.93
64 Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest Ophthalmol Vis Sci 2006 0.93
65 Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J Chem Technol Biotechnol 2005 0.92
66 HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J Immunol 2014 0.91
67 Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol 2005 0.91
68 Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res 2014 0.90
69 The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN. J Am Soc Nephrol 2013 0.89
70 CCR6: a biomarker for Alzheimer's-like disease in a triple transgenic mouse model. J Alzheimers Dis 2010 0.89
71 Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells. Immunology 2012 0.89
72 Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J Immunol 2005 0.87
73 Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-alpha and IL-1beta. Clin Immunol 2005 0.87
74 Transfer of severe experimental autoimmune encephalomyelitis by IL-12- and IL-18-potentiated T cells is estrogen sensitive. J Immunol 2003 0.86
75 17Beta-estradiol treatment profoundly down-regulates gene expression in spinal cord tissue in mice protected from experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz) 2003 0.86
76 A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J Neuroimmunol 2002 0.85
77 AlphaB-crystallin-reactive T cells from knockout mice are not encephalitogenic. J Neuroimmunol 2006 0.85
78 HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. J Neurosci Res 2004 0.85
79 Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice. Metab Brain Dis 2015 0.85
80 RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS. PLoS One 2011 0.83
81 Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice. Invest Ophthalmol Vis Sci 2012 0.83
82 Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. J Neurosci Res 2002 0.82
83 Opposing roles for TGF-beta1 and TGF-beta3 isoforms in experimental autoimmune encephalomyelitis. Cytokine 2004 0.82
84 TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. Eur J Immunol 2011 0.82
85 CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. J Neurosci Res 2003 0.82
86 CD4 T-cell epitopes of human alpha B-crystallin. J Neurosci Res 2004 0.81
87 Endogenous CD4+BV8S2- T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG-/- mice. J Neurosci Res 2003 0.81
88 Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis. Metab Brain Dis 2012 0.80
89 Inhibitory effects of incomplete Freund's adjuvant on experimental autoimmune encephalomyelitis. Autoimmunity 2002 0.79
90 Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) Foxp3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells. Immunology 2010 0.78
91 Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction. PLoS One 2013 0.78
92 Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease. Eur J Immunol 2006 0.77
93 Contribution of GPR30 for 1,25 dihydroxyvitamin D₃ protection in EAE. Metab Brain Dis 2011 0.77
94 The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metab Brain Dis 2014 0.75
95 Regulatory T cells play a role in T-cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis. Immunology 2012 0.75
96 Veterans Administration support for medical research: opinions of the endangered species of physician-scientists. FASEB J 2004 0.75
97 Evaluation of the Effects of 17β-Estradiol (17β-E2) on Gene Expression in Experimental Autoimmune Encephalomyelitis Using DNA Microarray. Endocrinology 2002 0.75